February 15, 2012 — Vessix Vascular Inc., developer of a novel percutaneous radiofrequency (RF) balloon catheter technology, announced that it will make its first detailed public presentation of preclinical data relating to its new V2 Renal Denervation System on Saturday, Feb. 18, 2012 at the TRenD Workshop 2012, in Frankfurt, Germany.
The presentation, titled "Percutaneous RF balloon-mediated renal denervation in under a minute: The V2 System by Vessix," will be made by James R. Margolis, M.D., during a session focused on emerging technologies for renal denervation.
Renal denervation is a percutaneous, catheter-based approach that disrupts renal sympathetic nerves whose hyperactivity leads to uncontrolled high blood pressure.
Margolis commented, "Vessix's pre-clinical data is the most robust I have seen in the field of renal denervation for hypertension. The data provides significant angiographic and histological evidence of safety and also effectiveness in reducing kidney norepinephrine levels – a surrogate for reduction of blood pressure in humans. The Vessix RF balloon catheter technology promises to place a very familiar tool in the hands of interventionalists and allow therapy to be safely delivered in seconds. I look forward to seeing the results of the upcoming multi-center international clinical study set to begin in Europe later this month."
Vessix's V2 Renal Denervation System for the treatment of drug resistant hypertension is an over the wire balloon catheter with electrodes mounted on the exterior of the balloon to facilitate the delivery of RF inside the renal artery. The patented catheter connects to a proprietary low power bipolar RF generator. After inflation in the artery, the balloon catheter's RF energy is activated for 30 seconds resulting in the disruption of the renal nerves located in the adventitia that surround the renal artery.
For more information: www.vessixvascular.com
October 30, 2024 
